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ABSTRACT  
Background: Vascular calcification independently predicts cardiovascular disease, the 
major cause of death in renal transplant recipients (RTR). Longitudinal studies of 
vascular calcification in RTR are few, small-sized and have a short follow-up. We 
assessed the evolution of coronary artery calcification (CAC) and thoracic aorta 
calcification (AoC) and their determinants in a cohort of prevalent RTR.  
Study Design: Longitudinal.  
Setting and participants: The Agatston score of coronary arteries and thoracic aorta was 
measured by 16-slice spiral computerized tomography (CT) in 281 RTR.  
Predictors: Demographic, clinical and biochemical parameters were recorded 
simultaneously.  
Outcomes and measurements: The Agatston score was again measured ≥ 3.5 years later.  
Results: A repeat analyzable CT was available in 197 RTR (70 %) after 4.40 (±0.28) 
years; it was not in the remaining patients due to death (n = 40), atrial fibrillation (n=1), 
other arrhythmias (n = 4), refusal (n = 35) or technical problems precluding confident 
calcium scoring (n=4). CAC and AoC scores increased significantly (by a median of 11% 
and 4% per year, respectively) over follow-up. By multivariable linear regression, a 
higher baseline CAC score, a history of cardiovascular event, the use of a statin and a 
lower 25-(OH) vitamin D3 level were independent determinants of CAC progression. 
Independent determinants of AoC progression were higher baseline AoC score, higher 
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pulse pressure, use of a statin, older age, higher serum level of phosphate, use of aspirin 
and male gender. Significant regression of CAC/AoC was not observed in this cohort. 
Limitations: cohort of prevalent RTR with potential survival bias; few diabetics and non 
Caucasians, limiting the generalizability of the results  
Conclusion: In contrast to previous small-sized short-term studies, we demonstrate that 
vascular calcification progression is substantial within 4 years in prevalent RTR and 
associated with several traditional and non-traditional cardiovascular risk factors, some of 
which are modifiable.  
 
Keywords : renal transplantation, vascular calcification, clinical determinants, 
cardiovascular disease
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INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of premature death in RTR, 
with a 3.5 to 5% annual risk of fatal or non-fatal CV events (CVE), much higher than in 
the general population despite adjustment for traditional risk factors (1, 2). A high 
prevalence of vascular calcification has been demonstrated in patients with chronic 
kidney disease (CKD), with higher calcification scores than in age- and gender-matched 
non-renal patients with coronary heart disease (3-5). Vascular calcification may involve 
either the intima, in association with inflammation and atherosclerosis, or the media, 
causing vascular stiffness. Both processes often coexist in advanced CKD and cannot be 
distinguished by imaging techniques, including computed tomography (CT) (6). Still, 
vascular calcification strongly predicts CVD and all-cause mortality not only in 
hemodialysis and peritoneal dialysis patients (7-9) but also in RTR (10-12). Moreover, 
coronary artery calcification (CAC) progression also predicts CVE and mortality in RTR 
(12). Only few small-sized studies relying on CT have assessed CAC progression in RTR 
(13-16).  
In the present study a large prevalent RTR cohort underwent CT at inclusion and 
~4 years later to assess the evolution of coronary artery and thoracic aorta calcification 
(AoC). The relationship between clinical, demographic, biological markers and 
calcification score at baseline and progression of vascular calcification was investigated. 
We hypothesized that vascular calcification progresses substantially in stable renal 
transplant recipients and that independent determinants of both CAC and AoC 
progression include both classical and non-classical cardiovascular (CV) risk factors.  
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PATIENTS AND METHODS 
Patients 
The prevalent Brussels Renal Transplant Cohort was initiated from February 3rd 
2004 to January 27th 2005. All RTR with a functional graft for ≥ 1 year attending the 
outpatient clinic of the Cliniques universitaires Saint Luc (UCL, Brussels) for their 
annual or bi-annual in-depth control were asked to enter the study. The protocol was 
approved by the Ethics Committee of the UCL Medical School and written informed 
consent was obtained from all patients. Exclusion criteria were age under 18, residing 
abroad or being recipient of a multi-organ transplant. Three hundred nineteen patients 
were contacted, 300 of whom entered the study. 
Spiral CT scan 
At inclusion 281 patients underwent chest multi-slice spiral CT on a 16-slice 
scanner (Brillance 16, Philips Healthcare, www.healthcare.philips.com). The thoracic 
aorta and the four branches of the main coronary arteries were individually scored as 
previously described (17). Agatston scores of coronary arteries (CAC) and thoracic aorta 
(AoC) were measured using a manufacturer algorithm (Heart Beat CS, Philips 
Healthcare, www.healthcare.philips.com) and expressed in mg. Intra-reader variability 
was 3 % and 8 % respectively for CAC and AoC (17). The Agatston score was again 
measured ≥ 3.5 years later. All CT studies were performed at baseline and follow-up on 
the same machine using the same conditions of CT acquisition and the same scoring 
software.  
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Clinical and biological parameters 
At baseline, demographic, clinical and medical history parameters including 
history of cardiovascular event (CVE)  (defined as myocardial, cerebrovascular or lower 
limb necrosis or revascularization or documented transient ischemic attack (18)) were 
recorded by reviewing medical charts. Blood samples were obtained at inclusion in order 
to measure in blood or serum creatinine, cholesterol, triglyceride, glycemia (Synchron 
CX®, Beckman Coulter, www.beckman.com), fibrinogen (Sysmex® CA 7000, Siemens, 
www.medical.siemens.com), homocysteine (ARCHITECT®, Abbott, www.abbott.com), 
25 (OH) and 1,25-(OH)2 vitamin D3 (LIAISON®, DiaSorin, www.diasorin.com), iPTH 
(Nichols, www.nicholsinstitute.com). Serum analysis for high-sensitivity CRP (hsCRP) 
was performed by immunonephelometry using a standard (Dade Behring Holding GmbH, 
www.dadebehring.com). Serum fetuin-A level was measured by nephelometry as 
previously described (19). Proteinuria was measured on a 24h urine collection. Blood 
pressure was measured with an automatic validated device (Omron® M5-I, 
www.omronhealthcare.com) after 10 min rest according to the JNC VII recommendations 
(20). Glomerular filtration rate was estimated by the abbreviated MDRD formula at time 
of inclusion. Induction and maintenance immunosuppressive drugs and all drugs 
prescribed at inclusion were recorded.  
Statistical analysis 
Results are presented as means ± SD, median [P25-P75] or n (and %) as 
appropriate. Variables presenting a right skewed distribution were log-transformed. 
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Univariate analysis was performed using the t-test, Wilcoxon sign-rank test or Chi-square 
test as applicable.  
Multiple stepwise linear regression using annualized absolute rate of change as a 
continuous variable was performed to identify determinants of CAC or AoC progression. 
We computed the annualized absolute rate of change of vascular calcification (CAC or 
AoC) as the difference of Agatston score between the first and second scan divided by 
the time between scans. The annualized absolute rates of change were log-transformed. 
 All variables reaching in univariate analysis the p < 0.2 level entered the 
multivariable models. To handle the major issue of competing risk for having a follow-up 
scan versus death, we performed sensitivity analyses with dead patients classified as 
having progression of CAC or AoC either similar or greater than the cohort. Similar CAC 
or AoC progression was defined as 14% or 10% (median) progression respectively, over  
4.4 years. Greater CAC or AoC progression was defined as 57% or 48% (third tertile) 
progression respectively, over 4.4 years. 
We compared non progressors, slow and high progressors. For this analysis we 
computed the percentage annualized rate as the absolute rate divided by the initial score 
(CAC or AoC). The analysis comparing non progressors, slow and high progressors 
included only patients with a score of 0 or higher than 30 because with low (but different 
from 0) baseline scores, there is a substantial risk of overestimation of the percentage 
change of score over time (15,21). For patients with CAC or AoC at baseline scored 0 or 
higher than 30, progressors were divided in three groups (tertiles). Subjects with a CAC 
or AoC score of 0 and a follow-up score > 4 were considered as high progressors (14).  
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All statistical analyses were performed using SPSS 15.0 software. All tests were 
two-tailed and a p-value < 0.05 was considered as significant. 
RESULTS 
 
Out of the initial 281 patients’ cohort, forty patients died before the appointment 
for the second CT and one had atrial fibrillation precluding a successful scan. Thirty-five 
declined to undergo a second CT. Two hundred and five patients thus had a repeat CT 
after 4.40 (± 0.28) years. Calcium scoring could not be performed in 8 patients of them, 
due to technical problems (n=4) or arrhythmias (n=4). Thus the study cohort included 
197 patients (Figure 1). Patients resuming dialysis (n=14) were not censored. 
1. Characteristics of the patients 
The 197 patients were 98 % Caucasian, 57 % male, aged 52 ± 12 years, 
transplanted for 93 ± 78 months (Table 1). A history of CVE was recorded in 48 patients 
(25 %). Blood pressure was 134 ± 20 / 82 ± 12 mmHg. Drugs at inclusion were 
azathioprine in 27 % (n = 53), mycophenolate mofetil (MMF) in 45 % (n = 88), 
cyclosporin in 47 % (n = 93), tacrolimus in 42 % (n = 82) and sirolimus in 8 % (n = 15). 
The cause of end-stage renal disease was chronic glomerulonephritis (n = 66; 34 %), 
chronic interstitial nephropathy (n = 60; 30 %), polycystic kidney disease (n = 38; 19 %), 
nephrosclerosis (n = 9; 5 %), diabetic nephropathy (n = 6; 3 %) and others/unknown (n = 
18; 9 %). We compared the 197 patients with a repeat analyzable CT with the 40 patients 
who died and the 40 without repeat analyzable CT for another reason (5 with arrhythmias 
and 35 who declined). They differed for age, history of CVE, systolic blood pressure, 
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pulse pressure, use of azathioprine and aspirin, time on dialysis, glucose, hsCRP, 
homocysteine, 25-(OH) vitamin D3, 1,25-(OH) vitamin and PTH levels (Table 1). 
2. Vascular calcification at baseline and follow-up  
At baseline CAC score was: mean 616 ± 1164 mg, median 110 [1 – 582] (Figure 
2).  CAC score was equal to 0 in 24.4 % (n = 48) of the subjects. At baseline AoC score 
was: mean 2384 ± 5635 mg, median 222 [6 – 1564] (Figure 2). AoC score was equal to 0 
in 18 % (n = 36) of the subjects. 
The follow-up CAC score was: mean 957 ± 1941, median 202 [8 – 936] (Figure 
2). The absolute annualized progression of CAC was: mean 79 (± 327), median 11 [1-58] 
(p <0.001) (Figure 3). Among subjects with an initial CAC score equal to 0, 83.3 % (n = 
40) again had a score of 0. The follow-up AoC score was: mean 2582 ± 5769, median 
294 [9 – 1750] (Figure 1). The absolute annualized AoC progression was: mean 54 (± 
404), median 5 [0-62] (p <0.001) (Figure 3). Among subjects with an initial AoC score 
equal to 0, 75 % (n = 27) again had a score of 0.  
The absolute annualized CAC and AoC progression were highly correlated 
(p<0.001) (Figure 4). A few individuals had decreases in CAC (n = 5) and/or in AoC (n = 
13). In some of them, these changes were (very) small and consistent with the  variability 
of the measure. In some others, careful review of paired scans ascribed apparent 
regressions to artifacts. Overall, there was no solid evidence of regression of either CAC 
or AoC in any patient.    
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3. Determinants of CAC progression  
Among patients with an initial CAC score of 0 or higher than 30 (n = 172), 55 
met the definition of high CAC progressors (Table 2). Age, gender, diabetes and 
homocysteine, parathyroid hormone and 25-(OH) vitamin D3 levels (but not graft 
function) were significantly different between non progressors, slow and high CAC 
progressors.  
By univariate regression analysis, older age, male gender, history of CVE, 
systolic blood pressure, pulse pressure, use of statin, time on dialysis, 25-(OH) vitamin 
D3 and PTH levels, and CAC baseline score were associated with annualized absolute 
CAC progression (Table 3). In a multivariable regression model, CAC baseline score, 
history of CVE, use of statin and level of 25-(OH) vitamin D3 were independently 
associated with the annualized absolute CAC progression (R² = 0.29, p<0.001) (Table 3). 
Sensitivity analyses performed in 237 patients did not change the determinants of CAC 
progression. The relationship between a low level of 25(OH)vitD3 and CAC progression 
was even strengthened in the greater progression analysis (Supplementary tables 1 and 2).  
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4. Determinants of AoC progression 
Among patients with an AoC score of 0 or higher than 30 (n = 166), 60 met the 
definition of high AoC progression (Table 4). Age, history of CVE, use of statin and 
cyclosporine, and levels of phosphate and 25-(OH) vitamin D3 (but not graft function) 
were significantly different between non progressors, slow and high AoC progressors.  
By univariate regression analysis, older age, male gender, history of CVE, 
diabetes, systolic blood pressure, pulse pressure, diabetes or hypertension as cause of 
ESRD, living donor TP, use of statin and aspirin, fetuin-A and phosphate levels as well as 
AoC baseline score were associated with annualized absolute AoC progression (Table 5). 
In a multivariable regression model AoC baseline score, pulse pressure, use of statin, age,  
phosphate level, use of aspirin and gender were independently associated with the 
annualized absolute AoC progression (R² = 0.42, p<0.001) (Table 5). Sensitivity analyses 
performed in 237 patients showed that determinants of AoC progression were largely 
unchanged in both the similar and greater progression analyses, with only phosphate level 
no longer reaching significance (p = 0.06) (Supplementary tables 3 and 4).   
DISCUSSION 
To the best of our knowledge, the current study is the first one to assess the 
progression of both CAC and AoC in a large population of stable RTR with a relatively 
long follow-up time. Our major finding is that vascular calcification progresses 
substantially within 4 years in prevalent RTR: CAC increased by a median of 11 % per 
year and AoC increased by a median of 4 % per year in RTR with a baseline vascular 
score higher than 30 (21). In 25 percent of patients the yearly increase of CAC and AoC 
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reached or exceeded 23 % and 17 % respectively. The independent determinants of both 
CAC and Aoc progression include both classical and non-classical CV risk factors, some 
of them modifiable. 
Only four series previously assessed the progression of CAC in RTR (13-16). All 
these cohorts were much smaller and intervals between CT scans were shorter. 
Mazzaferro et al. compared the 2-year CAC changes in 41 prevalent RTR transplanted 
(since at least 6 months) and in 30 dialyzed patients. Interestingly, the score increased in 
the dialysis group whereas it remained stable in RTR. The relatively small size of this 
study and limited duration of follow-up very likely accounts for the discrepancy with our 
results (13). The other 3 series were in incident RTR. Schankel et al. performed an EBCT 
in 82 patients at time of transplantation and at least one year later. They observed that 
CAC continues to progress after renal transplantation at a median yearly rate of 10.7 % in 
recipients with baseline calcification; one quarter of subjects had an increase of 25 % per 
year (14). In a small study performed in 31 patients, Oschatz et al. measured CAC 
immediately after renal transplantation and at 6 and 12 months. They observed a 
significant progression within the first 6 months but no significant change between the 6th 
and 12th months (15) whereas by design, our study did not assess CAC and AoC 
progression in the first year after transplantation. In contrast to Oschatz et al. (15), Moe et 
al. did not observe any CAC progression in a cohort of 23 patients who underwent a CT 
scan at the time of renal transplantation and 15 to 20 months later (16). Regarding AoC 
progression, data in RTR patients are limited to the 23 patients studied by Moe et al. 
Again, no significant progression of AoC was detected, in contrast to our study, probably 
as a result of a small cohort and short follow-up time.  
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Interestingly, we observe for the first time in RTR a positive correlation between 
the absolute annualized progression of CAC and AoC. A few patients showed an 
apparent decrease of either CAC or AoC. However, careful review of the few paired 
scans showing a decrease exceeding the variability of the measure did not confirm true 
regression but rather artifacts or inaccurate or at least slightly different technical aspects 
accounting for this apparent regression(s). Similar findings have recently been reported in 
a large cohort of 197 diabetics whose CAC and Abdominal aortic score were measured 
twice some 4 years apart (22). Of note, the exclusion of these paired scans with apparent 
regression does not change the independent determinants (see below) of CAC 
progression (data not shown) and very little those of Aoc progression (Table 5 versus 
Supplementary table 5).      
Our second aim was to investigate the determinants of vascular calcification 
progression in RTR. For CAC, these include a higher baseline CAC score, a history of 
CVE, the use of a statin and a lower 25-(OH) vitamin D3 level. Restricting the analysis to 
patients with a baseline score > 0 (n = 149) does not change the results (data not shown). 
That a higher baseline CAC score is associated with CAC progression confirms previous 
studies both in RTR (14) and in hemodialysis patients (13). Studies in dialysis patients as 
well as in renal transplant recipients have demonstrated the strong association of CVE 
history with CAC, the latter most likely related to atherosclerosis (23, 24, 25, 19), a 
hypothesis supported by our results of CVE history predicting CAC progression. Statin 
treatment at inclusion also predicts CAC progression in our cohort. This very likely 
reflects confounding by indication. This possibility is supported by the fact that when the 
analysis is restricted to patients without CVE history (n = 148), the relationship of 
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CAC/AoC progression with statin use is no longer significant. Moreover, whereas early 
observational studies performed in the general population and in diabetics demonstrated 
an association between the use of statin and slower CAC progression (26), more recent 
randomized trials demonstrated that statins do not change the progression of CAC (27). 
The fourth independent determinant of CAC progression was a low 25-(OH) vitamin D3 
level. In addition to its role in mineral and bone metabolism, vitamin D has many other 
pleiotropic effects. Circulating concentrations of 25-(OH) vitamin D3 are a sensitive 
measure of vitamin D status. Previous studies observed a negative correlation between 
vitamin D levels and the onset of CAC in HD patients (28), the prevalence of CAC in 
RTR (17), as well as the pulse wave velocity in HD patients (29). Moreover, in 52 stable 
hemodialysis patients, London et al. showed a positive correlation of 25-(OH) vitamin D3 
levels with brachial artery distensibility and flow-mediated dilation (29). These results 
support an association between vitamin D deficiency and arteriosclerosis as well as 
endothelial dysfunction. Interestingly, vitamin D treatment of osteoblastic cells inhibits 
calcification by decreasing type 1 collagen production, which plays an important role in 
calcium deposition (30). Observational studies already showed that vitamin D deficiency 
is associated with increased risks for cardiovascular disease and death in the general  
population (31, 32), with heart failure in patients referred for coronary angiography (33) 
and with mortality in hemodialysis and CKD patients (34, 35). Moreover low 25-(OH) 
vitamin D3 levels are associated with traditional atherosclerosis risk factors (36-39). 
These studies suggest a potential role for vitamin D therapy in these populations. 
Randomized controlled trials are thus required to test the potential benefits of vitamin D 
treatment on those outcomes. In incident RTR, diastolic blood pressure, GFR, BMI (14) 
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as well as smoking (15) were determinants of CAC progression. In our cohort of 
prevalent RTR, these parameters were not independent determinants of CAC progression.  
The independent determinants of AoC progression are a higher baseline AoC 
score, a higher pulse pressure, the use of a statin, older age, a higher level of phosphate, 
the use of aspirin and male gender. Restricting the analysis to patients with a baseline 
score > 0 (n = 161) did not change the results (data not shown). Older age and male 
gender are classical CV risk factors (23, 24, 18, 40). Like for CAC progression, use of 
statin and baseline score were associated with AoC progression. We also show an 
association of AoC progression with a higher pulse pressure, independently of baseline 
AoC. This association is of interest, as it suggests that a stiffer aorta could be a risk factor 
for the progression of aortic calcification, independently of the initial extent of the latter. 
A high pulse pressure (a surrogate for arterial stiffness) is indeed a well established 
cardiovascular risk factor (41) and both a cause and a consequence of atherosclerosis. 
The endothelium regulates the vascular tone and cardiovascular homeostasis. Endothelial 
dysfunction reduces nitric oxide (NO) bioavailability and is associated with the onset and 
progression of atherosclerosis (42-43) and with arterial calcification resulting in arterial 
stiffness (44-46). This link is further supported by an in vivo study showing that exercise 
prevented the decrease in eNOS expression and NO production and reduced arterial 
calcification in ovariectomized rats (47). Furthermore, other studies have reported an 
association between high pulse pressure and endothelial dysfunction (48-50). It was also 
observed that NO may regulate arterial distensibility, and thus possibly pulse pressure 
(51). On the other hand, the elevation of pulse pressure may also exert a negative 
feedback on the endothelium (52). Overall, these results are in line with our findings and 
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suggest that a high pulse pressure may be a risk factor for AoC progression. The use of 
aspirin at inclusion predicts AoC progression in our study. Like for the statins, this 
observation is probably related to confounding by indication. We also identified a higher 
phosphate level as predictor of AoC progression, independently of eGFR. Studies in 
healthy adults (53) and CKD patients (54) already observed an association of higher 
phosphatemia with atherosclerosis and vascular calcification. Russo et al. established in a 
cohort of predialysis patients that higher phosphorus levels were associated with CAC 
progression (55). Another study performed in CKD patients observed an association 
between higher phosphorus levels and mortality (56). Again, hypotheses generated by 
observational studies require testing in randomized trials, in order in this case to assess 
the impact of phosphate binders on survival or AoC progression (57).  
The strengths of our study, the first to examine the progression of both CAC and 
AoC in a large population of stable RTR, include the sample size, the 4-year follow-up, 
the use of an identical multi-slice spiral CT at baseline and follow-up. Some limitations 
should be acknowledged. First, the study population is typical of RTR followed in 
European centers, mostly Caucasian and with a lower prevalence of diabetes than in the 
United States. Second, all parameters (except the calcium scoring) were obtained once at 
inclusion, so that we could not perform a time-dependent covariate analysis. Third, there 
is certainly a selection bias. Indeed a repeat CT scan was available only in 205/281 
patients and analyzable in 197/281 (70%). Since the patients without repeat scoring 
overall had a worse CV risk profile at baseline (Table 1), our results probably 
underestimate somewhat the progression of vascular calcification in RTR. Sensitivity 
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analyses however showed that our results are robust. Finally, the inclusion of prevalent 
rather than incident RTR patients may have introduced a survival bias. 
In conclusion, the present study shows that vascular calcification progresses 
substantially in stable renal transplant recipients. The independent determinants of both 
CAC and Aoc progression include both classical and non-classical CV risk factors, some 
of them modifiable.  
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Table 1: Characteristics of the renal transplant recipients cohort, compared with patients 
without a second analyzable CT scan (dead and excluded) 
Variables 
 
Study cohort : with a 
second analyzable 
CT                                 
b                           g                          
g               
N = 197  
Mean ± SD 
Median [P25-P75] 
% 
Patients who died 
during follow-up 
(without a second 
analyzable CT scan)             
g  
N = 40 
Mean ± SD 
Median [P25-P75] 
% 
Patients who 
declined a second CT 
or had arrhythmias 
(without a second 
analyzable CT scan)  
N = 40 
Mean ± SD 
Median [P25-P75] 
% 
P-value 
Demographics and comorbidity 
        
         Age (y) 52 ± 12 63 ± 10 50 ±  14 <0.001 
         Male gender 57 72 68 0.1 
         BMI (kg/m²) 26 ± 5 27 ± 4 26 ± 5 0.6 
         Diabetes  13 23 12 0.3 
         History of CVE 25 69 27 <0.001 
         History of smoking 50 54 61 0.4 
         Current smoking 12 10 27 0.05 
         History of PTX 13 18 15 0.7 
Physical examination 
        
         Systolic BP (mmHg) 134 ± 20 146 ± 25 134 ± 16 0.01 
         Diastolic BP (mmHg) 82 ± 12 85 ± 17  82 ± 10 0.2 
         Pulse pressure (mmHg) 53 ± 17 60 ± 16 53 ± 11 0.04 
Drugs 
        
         Use of statin 37 41 44 0.7 
         Use of tacrolimus 42 44 39 0.9 
 25 
         Use of cyclosporin 47 46 54 0.7 
         Use of azathioprine 17 46 46 0.008 
         Use of sirolimus 8 15 7 0.3 
         Use of MMF 45 44 46 0.9 
         Use of aspirin 9 15 24 0.02 
         Use of            Use of calcium with/without vit D 35 56 42 0.05 
Kidney function and RRT 
characteristics 
        
         MDRD (ml/min/1.73m²) 53 ± 20 47 ± 18 52 ± 21 0.3 
         Time on dialysis (y) 2 ± 2 3 ± 3 2 ± 3 0.01 
         Creatinine (mg/dL) 1.6 ± 0.8 1.7 ± 0.9 1.6 ± 0.7 0.6 
         Diab/HT as cause of ESRD  8 21 7 0.07 
         Living donor TP  14 13 15 0.9 
Biological markers 
        
         Glucose (mg/dL) 92 [85-103] 103 [90-121] 89 [83-102] 0.03 
         hsCRP (mg/L) 1.43 [0.57-3.01] 3.35 [0.77-7.19] 1.51 [0.46-3.18] 0.02 
         Hemoglobin (g/dL) 13 ± 2 13 ± 2 13 ± 1 0.5 
         Homocysteine (µmol/L) 15 [13-18] 17 [14-23] 15 [13-19] 0.02 
         Proteinuria (g/24h) 0.12 [0.07-0.25] 0.17 [0.08-0.48] 0.15 [0.07-0.27] 0.4 
         Total cholesterol (mg/dL) 200 [175-226] 206 [185-244] 192 [175-216] 0.4 
         HDL cholesterol (mg/dL 58 [47-72] 59 [49-73] 54 [47-63] 0.3 
         25(OH)vitD3 (ng/mL) 15 [11-23] 10 [7-16] 15 [11-19] 0.01 
         1-25(OH)vitD3 (pg/mL) 33 [24-46] 28 [16-31] 28 [18-38] <0.001 
         Calcium (mg/dL) 10 ± 1 10 ± 1 10 ± 1 0.9 
         Phosphate (mg/dL) 3 ± 1 3 ± 1 3 ± 1 0.8 
         PTH (pg/mL) 40 [28-58] 60 [43-86] 42 [31-66] 0.01 
         Fetuin-A (g/L) 0.6 ± 0.1 0.6 ± 0.1 0.6 ± 1 0.8 
 26 
         OPG (pmol/L) 14 ± 9 17 ± 14 14 ± 8 0.2 
 
Note Table 1:  
Conversion factors for units: serum creatinine in mg/dL to µmol/L, x88.4; glucose in 
mg/dL to mmol/L, x0.05551; hemoglobin in g/dL to g/L, x10; total cholesterol in mg/dL 
to mmol/L, x0.02586; HDL cholesterol in mg/dL to mmol/L, x0.02586; 25(OH) vitD3 in 
ng/mL to nmol/L, x2.496; 1-25(OH) vitD3 in pg/mL to pmol/L, x2.6; calcium in mg/dL 
to mmol/L, x0.2495; phosphate in mg/dL to mmol/L, x0.3229; magnesium in mEq/L to 
mmol/L, x0.5; PTH in pg/mL to µmol/L, x11.1.
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Table 2: Comparison of non, slow and high CAC progressors (tertile 1: <1%; tertile 2: 1-
15%; tertile 3: >15%). 
Variables 
N=172 patients 
Non Progressors 
Tertile 1 
Mean (SD)  
Median [P25-P75] 
% 
N = 56 
Slow Progressors 
Tertile 2 
Mean (SD) 
Median [P25-P75] 
% 
N = 56 
High Progressors 
Tertile 3 
Mean (SD)  
Median [P25-P75] 
% 
N = 60 
p-value 
Annualized Relative rate of change of CAC (%) 0 [-1 to 0.7] 7 [4-12] 29 [21-42] 
  
Demographics and comorbidity 
        
         Age (y) 46 (14) 54 (9) 58 (10) <0.001 
         Male gender  45 65 66 0.02 
         BMI (kg/m²) 27 (4) 27 (5) 26 (5) 0.9 
         History of CVE  18 28 31 0.3 
         Diabetes 3 23 18 0.01 
         History of smoking  45 49 58 0.4 
         Current smoking  12 11 9 0.9 
         History of PTX 17 14 11 0.7 
Physical examination 
        
         Systolic BP (mmHg) 131 (19) 136 (16) 137 (24) 0.3 
         Diastolic BP (mmHg) 81 (11) 83 (11) 79 (13) 0.2 
         Pulse pressure (mmHg) 50 (18) 53 (11) 58 (21) 0.06 
Drugs 
        
         Use of statin  27 49 40 0.06 
         Use of tacrolimus   45 25 55 0.01 
         Use of cyclosporin  48 58 33 0.05 
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         Use of azathioprine 23 44 18 0.01 
         Use of sirolimus  5 4 16 0.04 
         Use of MMF  43 37 47 0.5 
         Use of aspirin 5 14 9 0.02 
         Use of calcium with/without vit D 33 32 40 0.6 
Kidney function and RRT characteristics 
        
         MDRD (ml/min/1.73m²) 55 (21) 55 (18) 50 (20) 0.3 
         Time on dialysis (y) 1.9 (1.6) 2.5 (2.3) 2.3 (2.7) 0.3 
         Creatinine (mg/dL) 1.5 (0.6) 1.5 (0.5) 1.7 (0.9) 0.07 
         Diab/HT as cause of ESRD 5 12 7 0.3 
         Living donor TP 20 11 11 0.3 
         Time of transplantation (y) 6.8 (6.0) 9.5 (7.2) 5.3 (4.5) 0.06 
Biological markers 
        
         Glucose (mg/dL) 93 (15) 107 (44) 99 (18) 0.05 
         hsCRP (mg/L) 3.0 (5.1) 2.0 (2.0) 3.5 (5.3) 0.3 
         Hemoglobin (g/dL) 13 (2) 13 (1) 13 (2) 0.9 
         Homocysteine (µmol/L) 15 (4) 16 (3) 17 (4) 0.01 
         Proteinuria (g/24h) 0.2 (0.4) 0.2 (0.2) 0.5 (1.7) 0.2 
         Total cholesterol (mg/dL) 196 (44) 203 (36) 212 (53) 0.2 
         HDL cholesterol (mg/dL 60 (18) 60 (19) 62 (20) 0.8 
         25(OH)vitD3 (ng/mL) 21 (10) 16 (8) 16 (7) 0.01 
         1-25(OH)vitD3 (pg/mL) 38 (19) 35 (19) 37 (17) 0.6 
         Calcium (mg/dL) 9.5 (0.4) 9.6 (0.6) 9.4 (0.5) 0.05 
         Phosphate (mg/dL) 3.0 (0.6) 3.0 (0.6) 3.3 (0.9) 0.1 
         Magnesium (mEq/L) 1.5 (0.2) 1.6 (0.2) 1.6 (0.2) 0.06 
         PTH (pg/mL) 42 (31) 49 (32) 64 (52) 0.01 
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         Fetuin-A (g/L) 0.59 (0.13) 0.56 (0.12) 0.58 (0.16) 0.4 
         OPG (pmol/L) 14 (9) 14 (8) 15 (8) 0.7 
 
Note table 2 
Conversion factors for units: serum creatinine in mg/dL to µmol/L, x88.4; glucose in 
mg/dL to mmol/L, x0.05551; hemoglobin in g/dL to g/L, x10; total cholesterol in mg/dL 
to mmol/L, x0.02586; HDL cholesterol in mg/dL to mmol/L, x0.02586; 25(OH) vitD3 in 
ng/mL to nmol/L, x2.496; 1-25(OH) vitD3 in pg/mL to pmol/L, x2.6; calcium in mg/dL 
to mmol/L, x0.2495; phosphate in mg/dL to mmol/L, x0.3229; magnesium in mEq/L to 
mmol/L, x0.5; PTH in pg/mL to µmol/L, x11.1.
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Table 3: Univariate and multivariable linear regression analysis of risk factors of 
annualized change in CAC score   
 Univariate Analysis Multivariable analysis* 
Variables 
N=197 patients 
Univariate coefficient 
(SE) 
95% CI  p-value Multivariable coefficient 
(SE) 
95% CI p-value 
Demographics and cormobidity             
         Age (y) 0.005 (0.001) 0.002 to 0.008 0.001       
        Female gender  -0.11 (0.04) -0.18 to -0.04 0.003       
         History of CVE  0.18 (0.04) 0.10 to 0.26 <0.001 0.11 (0.04) 0.03 to 0.18 0.005 
         History of smoking  0.05 (0.04) -0.02 to 0.13 0.1       
Physical examination             
         Systolic BP (mmHg) 0.002 (0.001) 0.000 to 0.004 0.04       
         Pulse pressure (mmHg) 0.003 (0.001) 0.001 to 0.0025 0.004       
Vascular calcification             
         CAC baseline 0.09 (0.01) 0.07 to 0.12 <0.001 0.07 (0.01) 0.04 to 0.10 <0.001 
Drugs             
         Use of statin  0.16 (0.04) 0.09 to 0.23 <0.001 0.09 (0.03) 0.02 to 0.16 0.01 
Kidney function and RRT 
characteristics 
            
         Time on dialysis (y) 0.02 (0.01) 0.004 to 0.04 0.02       
         Living donor TP -0.08 (0.05) -0.18 to 0.03 0.2       
Biological markers             
         Homocysteine (µmol/L) 0.26 (0.15) -0.033 to 0.55 0.08       
         25(OH)vitD3 (ng/mL) -0.23 (0.08) -0.37 to -0.06 0.008 -0.15 (0.07) -0.28 to 0.00 0.05 
         PTH (pg/mL) 0.20 (0.07) 0.06 to 0.33 0.004       
         Fetuin-A (g/L) -0.21 (0.14) -0.48 to 0.06 0.1       
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Notes Tables 3: 
*R² = 0.29, p < 0.001; Factors with a p-value < 0.2 in the univariate analysis entered the 
multivariable stepwise linear regression 
Conversion factors for units: 25(OH) vitD3 in ng/mL to nmol/L, x2.496; PTH in pg/mL 
to µmol/L, x11.1.
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Table 4: Comparison of non, slow and high AoC progressors (tertile 1: <0%; tertile 2: 0-
8%; tertile 3: > 8%) 
Variables 
N=166 patients 
Non Progressors 
Tertile 1 
Mean (SD) or 
Median [P25-P75] 
% 
N = 53 
Slow Progressors 
Tertile 2 
Mean (SD) or 
Median [P25-P75] 
% 
N = 53 
High Progressors 
Tertile 3 
Mean (SD) or 
Median [P25-P75] 
% 
N = 60 
p-value 
Annualized Relative rate of change of AoC (%) -1 [-4 to 0] 2 [0-4] 21 [14-50] 
  
Demographics and comorbidity 
        
         Age (y) 46 (14) 58 (9) 54 (10) <0.001 
         Male gender  55 62 57 0.7 
         BMI (kg/m²) 26 (4) 27 (5) 27 (5) 0.8 
         History of CVE  22 42 17 0.01 
         History of smoking  44 68 42 0.05 
         Current smoking  9 14 10 0.7 
         Diabetes 7 18 13 0.3 
         History of PTX 16 12 13 0.8 
Physical examination 
        
         Systolic BP (mmHg) 133 (17) 135 (19) 136 (21) 0.7 
         Diastolic BP (mmHg) 81 (11) 79 (11) 83 (12) 0.2 
         Pulse pressure (mmHg) 52 (19) 57 (18) 53 (15) 0.4 
Drugs 
        
         Use of statin  24 46 50 0.01 
         Use of tacrolimus   53 46 30 0.05 
         Use of cyclosporin  33 44 62 0.01 
         Use of azathioprine 26 26 28 0.9 
 33 
         Use of sirolimus  11 6 3 0.3 
         Use of MMF  42 42 45 0.9 
         Use of aspirin 6 16 8 0.2 
         Use of calium with/without vit D 27 38 43 0.2 
Kidney function and RRT characteristics 
        
         MDRD (ml/min/1.73m²) 55 (21) 51 (20) 51 (21) 0.5 
         Time on dialysis (y) 2.0 (1.9) 2.7 (2.8) 2.0 (2.0) 0.2 
         Creatinine (mg/dL) 1.5 (0.6) 1.5 (0.5) 1.7 (1.0) 0.4 
         Diab/HT as cause of ESRD 9 8 7 0.9 
         Living donor TP 18 4 13 0.08 
         Time of transplantation (y) 6.9 (6.8) 7.6 (6.6) 7.6 (5.8) 0.8 
Biological markers 
        
         Glucose (mg/dL) 95 (32) 99 (22) 99 (17) 0.2 
         hsCRP (mg/L) 4.2 (7.8) 2.9 (5.3) 2.8 (2.5) 0.6 
         Hemoglobin (g/dL) 13 (2) 14 (2) 13 (1) 0.1 
         Homocysteine (µmol/L) 15 (4) 16 (4) 16 (4) 0.1 
         Proteinuria (g/24h) 0.2 (0.3) 0.2 (0.2) 0.6 (1.6) 0.2 
         Total cholesterol (mg/dL) 196 (34) 206 (46) 210 (47) 0.3 
         HDL cholesterol (mg/dL 59 (16) 60 (19) 64 (22) 0.4 
         25(OH)vitD3 (ng/mL) 19 (10) 16 (8) 15 (6) 0.01 
         1-25(OH)vitD3 (pg/mL) 38 (18) 34 (16) 35 (21) 0.6 
         Calcium (mg/dL) 9.5 (0.5) 9.5 (0.5) 9.5 (0.7) 0.9 
         Phosphate (mg/dL) 3.0 (0.7) 3.1 (0.6) 3.3 (0.9) 0.04 
         Magnesium (mEq/L) 1.5 (0.2) 1.6 (0.2) 1.6 (0.2) 0.2 
         PTH (pg/mL) 51 (50) 57 (42) 60 (49) 0.6 
         Fetuin-A (g/L) 0.59 (0.11) 0.57 (0.15) 0.58 (0.13) 0.8 
 34 
         OPG (pmol/L) 14 (11) 16 (9) 13 (7) 0.2 
 
Note table 4 
Conversion factors for units: serum creatinine in mg/dL to µmol/L, x88.4; glucose in 
mg/dL to mmol/L, x0.05551; hemoglobin in g/dL to g/L, x10; total cholesterol in mg/dL 
to mmol/L, x0.02586; HDL cholesterol in mg/dL to mmol/L, x0.02586; 25(OH) vitD3 in 
ng/mL to nmol/L, x2.496; 1-25(OH) vitD3 in pg/mL to pmol/L, x2.6; calcium in mg/dL 
to mmol/L, x0.2495; phosphate in mg/dL to mmol/L, x0.3229; magnesium in mEq/L to 
mmol/L, x0.5; PTH in pg/mL to µmol/L, x11.1. 
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Table 5: Univariate and multivariable linear regression analysis of risk factors of 
annualized change in AoC score 
 
Univariate analysis Multivariable analysis* 
Variables 
N = 197 patients 
Univariate 
coefficient (SE) 
CI 95% p-value Multivariable 
coefficient (SE) 
CI 95% p-value 
Demographics and cormobidity 
            
         Age (y) 0.013 (0.002) 0.01 to 0.02 <0.001 0.006 (0.002) 0.001 to 0.01 0.01 
         Female gender  -0.12 (0.05) -0.22 to -0.03 0.01 -0.09 (0.04) -0.17 to -0.01 0.03 
         History of CVE  0.21 (0.06) 0.11 to 0.34 <0.001 
      
         Diabetes 0.15 (0.07) 0.01 to 0.30 0.04 
      
Vascular calcification 
            
         AoC baseline 0.12 (0.02) 0.09 to 0.16 <0.001 0.06 (0.02) 0.02 to 0.10 0.008 
Physical examination 
            
         Systolic BP (mmHg) 0.004 (0.001) 0.002 to 0.01 <0.001 
      
         Pulse pressure (mmHg) 0.007 (0.001) 0.004 to 0.01 <0.001 0.003 (0.001) 0.001 to 0.01 0.01 
Drugs 
            
         Use of statin  0.22 (0.05) 0.13 to 0.32 0.01 0.11 (0.04) 0.02 to 0.20  0.01 
         Use of tacrolimus   -0.08 (0.05) -0.18 to 0.02 0.0 
      
         Use of cyclosporin  0.07 (0.05) -0.02 to 0.17 0.1 
      
         Use of aspirin 0.27 (0.09) 0.10 to 0.44 0.002 0.16 (0.07) 0.02 to 0.31 0.03 
Kidney function and RRT 
characteristics 
            
         Time on dialysis (y) 0.02 (0.01) -0.002 to 0.04 0.07 
      
         Diab/HT as cause of ESRD 0.24 (0.09) 0.08 to 0.52 0.01 
      
         Living donor TP -0.24 (0.07) -0.36 to -0.09 0.001 
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Biological markers 
            
         Glucose (mg/dL) 0.48 (0.28) -0.08 to 1.10 0.09 
      
         25(OH)vitD3 (ng/mL) -0.006 (0.003) -0.09 to 0.001 0.09 
      
         Phosphate (mg/dL) 0.07 (0.03) 0.01 to 0.13 0.03 0.47 (0.20) 0.08 to 0.86 0.02 
         Fetuin-A (g/L) -0.41 (0.18) -0.76 to -0.05 0.03 
      
         OPG (pmol/L) 0.005 (0.003) 0.000 to 0.01 0.06 
      
 
Notes Tables 5: 
*R² = 0.42, p < 0.001; Factors with a p-value < 0.2 in the univariate analysis entered the 
multivariable stepwise linear regression 
Conversion factors for units: glucose in mg/dL to mmol/L, x0.05551; 25(OH) vitD3 in 
ng/mL to nmol/L, x2.496; phosphate in mg/dL to mmol/L, x0.3229 
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Figure legends: 
Figure 1: Flow chart describing movement of the patients through the study 
Figure 2: Progression of CAC (A) and AoC (B) Agatson score (mg) in prevalent renal 
transplant recipients. Results are presented as median [P25-P75]. 
Figure 3: Distribution of the annualized rate of change of CAC (A) and AoC (B).  
Figure 4: Correlation between the absolute CAC and AoC progression per year.  
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Supplementary materials:  
Supplementary Figure 1: A and B) Axial CT image at time of inclusion (40 mg) (A) 
and at follow-up (270 mg) (B) at the level of the left main coronary artery. There is 
evidence of CAC progression. C and D) Sagittal CT image using a maximal intensity 
projection (MIP) at time of inclusion (317 mg) (C) and at follow-up (1284 mg) (D) at the 
level of the aorta. There is evidence of AoC progression. 
Supplementary table 1: Sensitivity analysis assuming patients who died had 14% CAC 
progression  
Supplementary table 2: Sensitivity analysis assuming patients who died had 57% CAC 
progression  
Supplementary table 3: Sensitivity analysis assuming patients who died had 10% AoC 
progression  
Supplementary table 4: Sensitivity analysis assuming patients who died had 48% AoC 
progression  
Supplementary table 5: Independent determinants of AoC progression in renal 
transplant recipients by multivariable linear regression (after exclusion of 13 patients 
with apparent AoC regression)  
 
 
 
 
 
